Clinical relevance of stress neuroadaptation in tobacco dependence
National Institute on Drug Abuse (R01 DA033809)
John Curtin (PI), Timothy Baker (Co-I), Megan Piper (Co-I), Daniel Bolt (Co-I)
Direct costs: $1,508,145
Status: Funded. 08/2012 – 06/2018
Neuroscience research with animal models implicates neuroadaptation in the stress response as a critical mechanism in the etiology of addiction across multiple classes of drugs including nicotine. Repeated homeostatic adjustments in the brain’s stress systems due to chronic drug administration eventually lead to persistent compensatory adaptations in the structures involved in emotional response and its regulation. Among smokers, these stress neuroadaptations result in dysregulated negative affect when nicotine-deprived and provide the strong motivational press for further smoking that manifests as urge and increased risk for smoking cessation failure.
Animal models have provided substantial evidence to support this stress neuroadaptation thesis in addiction. However, programmatic laboratory research that examines the stress response in nicotine deprived relative to non-deprived smokers is necessary to confirm that our understanding of stress neuroadaptations from animal models translate to addiction etiology in smokers. Negative affect is the core motivational element of the human drug withdrawal syndrome across additive drugs including nicotine. Unfortunately, much of what we know about these motivationally critical affective processes in humans is based on a narrow range of measures collected in isolation. The examination of the characteristics and neurobiological substrates of negative affect has not kept pace with the rapid conceptual, methodological, and measurement advances in the affective sciences over the past decade. Moreover, complementary methods (e.g., laboratory task manipulations, clinical treatment interventions) and measurement approaches (e.g., psychophysiology, ecological momentary assessment) are rarely combined.
The research in this application capitalizes on recent research with both animals and humans has synthesized precise laboratory manipulations of stress with sensitive psychophysiological measurement of startle reflex potentiation to parse the affective response to stress into its constituent components. In particular, startle potentiation during unpredictable (vs. predictable) threats holds promise as a biomarker of stress neuroadaptation following chronic nicotine or other drug use. We propose to measure stress neuroadaptation in the laboratory via startle potentiation during unpredictable threat in a validated cued threat tasks among nicotine deprived and non-deprived smokers. Smokers will be subsequently assigned to combination nicotine replacement therapy (NRT) or placebo during smoking cessation treatment and will report on episodic stressors, negative affect, smoking urge, and smoking via ecological momentary assessment procedures. Treatment outcome will be assessed at 2 weeks post-quit.
The broad goals of this research are to identify etiologically relevant psychophysiological biomarkers of stress neuroadaptation that results from chronic smoking. We evaluate the impact of this stress neuroadaptation on smokers’ real-world affect, urge and smoking during smoking cessation treatment. We also evaluate if NRT can attenuate the influence of this stress neuroadaptation on smoking cessation outcomes via its effects on withdrawal.